Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal lung disease characterized by the scarring of lung tissue. While there is no cure for IPF, various pharmaceutical companies are involved in the development and marketing of treatments to manage and slow the progression of the disease.
Pliant Therapeutics Positive Phase 2a data for their lead drug bexotegrast showed improvements in lung function and reduced fibrosis markers. This success has boosted their stock price and raised hopes for a potential breakthrough in IPF treatment.
Cumberland Pharmaceuticals Received FDA clearance for an Investigational New Drug (IND) application for their drug ifetroban to be tested in a Phase II study for IPF. This marks a significant step forward for their clinical development program.
Boehringer Ingelheim Announced positive topline results from their Phase IIb study evaluating nintedanib in combination with pirfenidone for IPF. This could potentially lead to new treatment options for patients who don't respond well to existing therapies.
Calluna Pharma Formed through the merger of Oxitope Pharma and Arxx Therapeutics, focusing on developing novel therapies for inflammatory and fibrotic diseases, including IPF.
Roche and Gilead Sciences Partnered to explore the potential of combining their respective drugs, Esbriet and pirfenidone, for IPF treatment. This collaboration could lead to more effective combination therapies.
Idiopathic Pulmonary Fibrosis Treatment Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)